Who is sponsoring NCT04485026?

NCT04485026 is sponsored by Wake Forest University Health Sciences.

What drugs are being tested in NCT04485026?

Interventions in NCT04485026: Local consolidative radiation therapy, Standard of care radiation therapy.

What condition does NCT04485026 study?

NCT04485026 studies Non Small Cell Lung Cancer, Oligoprogressive.

Is NCT04485026 still recruiting?

NCT04485026 is currently withdrawn. Last updated 17 April 2025.

Last reviewed 2025-04-17 · How we verify

NCT04485026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma

Withdrawn Phase 2 Last updated 17 April 2025

What this trial tests

Phase 2 trial testing Local consolidative radiation therapy in Non Small Cell Lung Cancer. Withdrawn.

Timeline

4 November 2020

Primary endpoint
9 May 2024

9 May 2024

Quick facts

Lead sponsor	Wake Forest University Health Sciences
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	4 November 2020
Primary completion	9 May 2024
Estimated completion	9 May 2024

Drugs / interventions tested

Local consolidative radiation therapy
Standard of care radiation therapy — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Oligoprogressive — all drugs for Oligoprogressive →

Sponsor

Wake Forest University Health Sciences

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Oligoprogressive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have progressed through first line systemic therapy containing an immune checkpoint inhibitor (ICI).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Oligometastatic Head and Neck Cancer: Challenges and Perspectives.
Bahig H, Huang SH, O'Sullivan B. · · 2022 · cited 19× · PMID 36010888 · DOI 10.3390/cancers14163894
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Prelaj A, Pircher CC, Massa G, Martelli V, et al · · 2021 · cited 15× · PMID 33803958 · DOI 10.3390/cancers13061300
How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.
Remon J, Menis J, Levy A, De Ruysscher DKM, et al · · 2021 · cited 14× · PMID 34430382 · DOI 10.21037/tlcr-20-1065

Verify or expand the search:

Other trials of Local consolidative radiation therapy

Trials testing the same drug.

NCT05278052 — Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC · Phase 3 · recruiting

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04485026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 17 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04485026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing